Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Primedicine In-Licenses China Rights to Heart Attack Treatment

publication date: May 19, 2020

Qingdao Primedicine Pharma in-licensed greater China rights to a novel drug that lowers damage following a heart attack from Primary Peptides of Vancouver, Canada. A clinical-stage company, Primary Peptides develops novel products based on disrupting specific protein-protein interactions. Previously, it has out-licensed China rights for other candidates to Simcere and Yabao Pharma. Primedicine is developing first-in-class treatments for addiction, Alzheimer’s disease, stroke, depression and other indications. Financial terms of the agreement were not disclosed. More details....

Share this with colleagues:


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital